Polycystic Ovarian Syndrome Drugs Market Expected To Be Valued US$ 1,154.8 Mn By 2024

According to the latest market report published by Persistence Market Research titled ‘Polycystic Ovary Syndrome Drugs Market: Global Industry Analysis and Forecast, 2016–2024’, the global polycystic ovary syndrome drugs market is expected to register a CAGR of 4.6% during the forecast period 2016–2024 and is expected to expand 1.5x in terms of revenue by 2024. The report analyzes the global PCOS drugs market performance and provides information on key drivers and trends likely to impact the market during the forecast period.

Growth of the global polycystic ovary syndrome drugs market is mainly driven by increasing prevalence of the disease and a growing awareness among the patient population. Increasing purchasing power among people and rising awareness of PCOS are factors expected to drive growth of the global PCOS drugs market.

The need for effective management of diseases associated with PCOS such as hirsutism, obesity, and infertility is likely to boost the demand for PCOS drugs. Also, a growing popularity of combination drugs and their rising adoption among the patient population is expected to boost revenue growth of the PCOS drugs market in the coming years.

A rising expenditure on research and development activities and introduction of novel drugs is further expected to boost growth of the global polycystic ovary syndrome drugs market over the forecast period. However, lack of FDA approved drugs, a low level of awareness of PCOS in underdeveloped countries, and increasing side effects associated with generics might hamper market growth during the forecast period.

To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/3682

Key Findings of the Report:

To investigate the competitive landscape – product launches, expansions, collaborations and acquisitions in the market.
To analyze and research the global market landscape and growth outlook, which includes, revenue, production, consumption, historical and forecast.
To recognize important drivers, restraints, opportunities, and threats (DROT Analysis)(SWOT Analysis).
To tactically examine the growth pattern and contribution to the market of every segment.

The global market for PCOS drugs presents several growth opportunities for market players. There is a good growth potential in emerging markets and pharmaceutical drugs manufacturers are focusing on emerging economies in the Asia Pacific and Africa such as Kenya, Nigeria, etc. to target a large patient population.

Also, effective reimbursement policies and reduction in the costs of drugs used for the treatment of PCOS is likely to increase the adoption of PCOS drugs across the globe. Leading market players are also investing significantly in developing new branded drugs to treat PCOS, owing to an anticipated high rise in the global patient population. The demand for branded PCOS drugs is likely to increase significantly during the forecast period.

The global PCOS drugs market is segmented based on Drug Class into Oral Contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors, and Diuretics.

For Critical Insights On The Polycystic Ovarian Syndrome Drugs Market, Request For Customization Here @ https://www.persistencemarketresearch.com/request-customization/3682

The contraceptive drug class segment is projected to register a CAGR of 5.4% over the forecast period. Oral contraceptives are generally the preferred first line therapy for the treatment of PCOS as they are easily available as OTC drugs.

The insulin sensitizing agent segment is expected to register a CAGR of 4.8% over the forecast period. About 70% of PCOS patients are overweight and are in the category of possible candidates for type 2 diabetes. As a result, insulin sensitizing agents are the widely prescribed drugs for the treatment of PCOS today. In terms of value, the oral contraceptives and insulin sensitizing agents drug class segments are collectively expected to remain the dominant and most attractive segments over the forecast period.

The global PCOS drugs market is segmented based on Distribution Channel into Hospital Pharmacies, Drug Stores/OTC, E-Commerce, and Fertility Clinics. The hospital pharmacies segment is likely to lead the global PCOS drugs market in terms of revenue growth and is estimated to be valued at US$ 575.4 Mn by the end of 2024. In terms of value, the drugs stores/OTC segment is estimated to account for 27.0% share of the overall market by the end of 2016.

On the basis of region, the market has been segmented into North America, Latin America, Europe, Asia Pacific, and the MEA. The North America market is expected to emerge as the dominant market for polycystic ovary syndrome drugs owing to a high diagnosis rate and increasing adoption of prescription drugs. North America is estimated to dominate the PCOS drugs market with maximum value share of the overall market by the end of 2016.

The presence of well-established pharmaceutical companies in North America as well as a relatively high instance of patients being diagnosed in hospitals for PCOS is a major driver for market growth. The market in the Asia Pacific region is expected to register the highest CAGR of 5.5% over the forecast period.

Significant increase in healthcare services spending along with rapid economic growth and increasing awareness about health issues are some of the key factors likely to push the sales of PCOS drugs in the APAC market.

For In-Depth Competitive Analysis, Buy Now @ https://www.persistencemarketresearch.com/checkout/3682

Company Profiles

Novartis AG
Teva Pharmaceutical Industries Limited
Addex Therapeutics Ltd.
BIOCAD
Merck KGaA
AstraZeneca plc.
Bristol Myers Squibb Co.
Ferring Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc.
Others

More About the Report –

Unprecedented access to a world of information has given rise to the empowered, albeit distrustful, consumer. So is the case with healthcare, where the patient has been rendered more informed and conscientious thanks to the extraordinary penetration of the Internet. The discerning patient now demands more affordable, sophisticated, transparent, and personalized healthcare services, creating the need for new models for care.

The advent of health information technology (HIT) components such as electronic health records (EHR), hospital information systems (HIS), picture archiving and communication systems (PACS), and vendor-neutral archives (VNA) has had just as transformational an impact on the overall healthcare sector as the concerns regarding security and privacy. Data theft, undue access to personal health records, and cyber-attacks are very real threats that the healthcare sector faces today.

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Molecular Diagnostics Market –

Molecular Diagnostics Market Segmentation by Key Players – Novartis AG, Roche Diagnostics, QIAGEN, Siemens Healthcare, Abbott Laboratories, Inc., Gen-Probe, Inc. (Hologic Inc.), Cepheid, Inc., Beckman Coulter, Inc., Becton, Dickinson & Company, Myriad Genetics, Inc., and bioMerieux.

Next-Generation Sequencing Market –

Next Generation Sequencing Market Segmented by(By Application – Whole-genome Sequencing ,Exome Sequencing,Targeted Resequencing,De Novo Sequencing,RNA Sequencing,ChIP Sequencing,Methyl Sequencing,Others);By Technology- Targeted Sequencing & Resequencing,Whole Genome Sequencing,Whole Exome Sequencing.

Ophthalmology devises Market –

Ophthalmology devises Market Segmentation by Key Players – Abbott Medical Optics Inc., Carl Zeiss Meditec AG, Bausch & Lomb Inc., Essilor International S.A, Ziemer Ophthalmic Systems AG and Topcon Corporation.

Intravenous Iron Drugs Market –

Intravenous (IV) Iron Drugs Market Segmentation by Key Players- Actavis, Inc., AMAG Pharmaceuticals, Inc., Galenica Ltd., Fresenius Medical Care AG & Co. KGaA, Vifor Pharma Ltd., American Regent, Inc., Luitpold Pharmaceuticals, Inc., Pharmacosmos A/S, Rockwell Medical Technologies, Inc., and Sanofi.

Syndromes Progressive Ataxia Weakness Disorders Market –

Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Market Segmentation by Key Players- Abbott Laboratories, Acorda Therapeutics Inc., American Regent Inc., Baxter International Inc., Biogen Idec., Bristol-Myers Squibb, Cadila Healthcare Ltd., Eli Lilly and Company, Glaxosmilthkline Plc., Sanofi, Roche Holding Ltd., Pfizer Inc. and Novartis AG.

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

305 Broadway, 7th Floor
New York City, NY 10007
United States
Ph.no. +1-646-568-7751
E-mail id- [email protected]
Website: https://www.persistencemarketresearch.com